First HAART in HIV-infected patients with high viral load: Value of HIV RNA levels at 12 weeks to predict virologic outcome

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 5, 2009, Pages 314-317

  Townsend, David ^a   Troya, Jesús ^b   Maida, Ivana ^c   Pérez Saleme, Leticia ^d   Satta, Giovanni ^c   Wilkin, Aimee ^a   Barreiro, Pablo ^b   Pegram, P Samuel ^a   Soriano, Vincent ^b   Mura, Maria Stella ^c   Núñez, Marina ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b Hospital Carlos   (Spain)

^c Istituto Malattie Infettive   (Italy)

^d HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

HAART; high viral load; HIV; resistance mutations; virologic failure

Indexed keywords

VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; CLINICAL TRIAL; FEMALE; GENETICS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUTATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 75349106109     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109709343966     Document Type: Article

References (11)

1. Wood E., Hogg R., Yip B., et al. Higher baseline levels of plasma HIV type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis. 2003 ; 188 (10). 1421-1425. (Pubitemid 37523926)
2. Mussini C., Manzardo C., Johnson M., et al, for the Late Presenter Investigators. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008 ; 22 (18). 2461-2469.
3. Lima V., Harrigan R., Murray M., et al. Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS. 2008 ; 22 (17). 2371-2380.
4. Metzner K., Allers K., Rauch P., Harrer T. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naïve patients. AIDS. 2007 ; 21 (6). 703-711. (Pubitemid 46568627)
5. DHSS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://AIDSInfo.nih.gov. Accessed November 3, 2008.
6. Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naïve and adherent patients. Clin Infect Dis. 2009 ; 48 (2). 239-247.
7. Riddler S., Haubrich R., DiRienzo G., et al, for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 ; 358 (20). 2095-2106. (Pubitemid 351679596)
8. Von Wyl V., Yerli S., Boni J., et al, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med. 2007 ; 167 (16). 1782-1790. (Pubitemid 47403067)
9. Gupta R., Hill A., Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008 ; 47 (5). 712-22.
10. Bartlett JA, Buda JJ, von Cheele B., et al. Minimizing resistance consequences after virological failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006 ; 41 (3). 323-331.
11. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007 ; 45 (suppl 1). S14 - S18.